At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed adenocarcinoma of stomach or gastroesophageal junction (esophageal adenocarcinoma not involving GE junction excluded)
- ✓Complete en bloc resection of all known tumor with curative intent
- ✓Tumor extension beyond muscularis propria and/or nodal involvement without M1 disease; eligible stages: IB (with N1 or T>muscularis propria), II, IIIA, IIIB, or IV (M0 only)
- ✓ECOG performance status 0, 1, or 2
- ✕Stages 0, IA, or any stage with M1 metastatic disease
- ✕Unresected cancer, recurrent cancer, positive margins, noncontiguous resection, or M1 disease
- ✕Any prior chemotherapy or radiotherapy
- ✕Uncontrolled cardiac conditions: high blood pressure, unstable angina, symptomatic CHF, MI <6 months, serious arrhythmia, or NYHA class III/IV
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma
In Brief
A Phase 3 clinical trial evaluating cisplatin, epirubicin hydrochloride, and 3 other interventions for Esophageal Cancer and Gastric Cancer. Completed, enrolled 546 participants across 535 sites in 2 countries.
Detailed Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy after surgery may kill any remaining tumor cells following surgery. It is not yet known which chemotherapy and radiation therapy regimen is more effective in treating stomach or esophageal cancer. PURPOSE: Randomized phase III trial to compare two different chemotherapy and radiation therapy regimens in treating patients who have undergone surgery for stomach or esophageal cancer.
Study Details
Timeline
Interventions
Given IV
Given IV
Given IV
Given IV
Given 5 days a week for 5 weeks